David L Gordon

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8749444/publications.pdf

Version: 2024-02-01

107 papers 3,790 citations

34 h-index 57 g-index

108 all docs

108 docs citations

108 times ranked 5414 citing authors

#	Article	IF	CITATIONS
1	Ocular syphilis. Survey of Ophthalmology, 2022, 67, 440-462.	1.7	39
2	Safety, immunogenicity, and efficacy of a Clostridioides difficile toxoid vaccine candidate: a phase 3 multicentre, observer-blind, randomised, controlled trial. Lancet Infectious Diseases, The, 2021, 21, 252-262.	4.6	38
3	Potential for bacteriophage therapy for <i>Staphylococcus aureus</i> pneumonia with influenza A coinfection. Future Microbiology, 2021, 16, 175-184.	1.0	4
4	Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19. Nature Communications, 2021, 12, 1162.	5.8	316
5	Changes in complement alternative pathway components, factor B and factor H during dengue virus infection in the AG129 mouse. Journal of General Virology, 2021, 102, .	1.3	7
6	Intra-abdominal infection with Campylobacter curvus: case report and review of the literature. Access Microbiology, 2021, 3, 000227.	0.2	0
7	Conventional myelosuppressive chemotherapy for non-haematological malignancy disrupts the intestinal microbiome. BMC Cancer, 2021, 21, 591.	1.1	11
8	Protective role of PhtD and its amino and carboxyl fragments against pneumococcal sepsis. Vaccine, 2021, 39, 3626-3632.	1.7	7
9	Successful treatment of cutaneous Acanthamoeba castellanii infection with miltefosine in a patient with chronic lymphocytic leukaemia on ibrutinib. Journal of Antimicrobial Chemotherapy, 2021, , .	1.3	2
10	Surgical Antibiotic Prophylaxis in an Era of Antibiotic Resistance: Common Resistant Bacteria and Wider Considerations for Practice. Infection and Drug Resistance, 2021, Volume 14, 5235-5252.	1.1	40
11	Cost effectiveness of treatment models of care for hepatitis C: the South Australian state-wide experience. European Journal of Gastroenterology and Hepatology, 2020, 32, 1381-1389.	0.8	4
12	Proteomic profiling of precipitated Clostridioides difficile toxin A and B antibodies. Vaccine, 2020, 38, 2077-2087.	1.7	2
13	Detectable Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Human Breast Milk of a Mildly Symptomatic Patient With Coronavirus Disease 2019 (COVID-19). Clinical Infectious Diseases, 2020, 72, 128-130.	2.9	79
14	Management of pyogenic liver abscess: a South Australian experience. ANZ Journal of Surgery, 2020, 90, 2274-2278.	0.3	4
15	<i>Mycoplasma hominis</i> bursitis in a simultaneous pancreasâ€kidney transplant recipient: case report and literature review. Transplant Infectious Disease, 2020, 22, e13392.	0.7	3
16	Improving Risk–Benefit in Faecal Transplantation through Microbiome Screening. Trends in Microbiology, 2020, 28, 331-339.	3.5	19
17	Dengue virus and the complement alternative pathway. FEBS Letters, 2020, 594, 2543-2555.	1.3	20
18	A Dimerization Site at SCR-17/18 in Factor H Clarifies a New Mechanism for Complement Regulatory Control. Frontiers in Immunology, 2020, 11, 601895.	2.2	3

#	Article	IF	CITATIONS
19	Efficacy of Lytic Phage Cocktails on Staphylococcus aureus and Pseudomonas aeruginosa in Mixed-Species Planktonic Cultures and Biofilms. Viruses, 2020, 12, 559.	1.5	23
20	Case report: Identification of intra-laboratory blood culture contamination with Staphylococcus aureus by whole genome sequencing. Diagnostic Microbiology and Infectious Disease, 2019, 94, 331-333.	0.8	2
21	Bacterial viability in faecal transplants: Which bacteria survive?. EBioMedicine, 2019, 41, 509-516.	2.7	84
22	AMEND study protocol: a case–control study to assess the long-term impact of invasive meningococcal disease in Australian adolescents and young adults. BMJ Open, 2019, 9, e032583.	0.8	3
23	Optimisation of a propidium monoazide based method to determine the viability of microbes in faecal slurries for transplantation. Journal of Microbiological Methods, 2019, 156, 40-45.	0.7	15
24	Impact of Long-Term Erythromycin Therapy on the Oropharyngeal Microbiome and Resistance Gene Reservoir in Non-Cystic Fibrosis Bronchiectasis. MSphere, 2018, 3, .	1.3	58
25	Sustained improvement in vancomycin dosing and monitoring post-implementation of guidelines: Results of a three-year follow-up after a multifaceted intervention in an Australian teaching hospital. Journal of Infection and Chemotherapy, 2018, 24, 103-109.	0.8	15
26	Not Just Antibiotics: Is Cancer Chemotherapy Driving Antimicrobial Resistance?. Trends in Microbiology, 2018, 26, 393-400.	3.5	46
27	Interventions targeting the prescribing and monitoring of vancomycin for hospitalized patients: a systematic review with meta-analysis. Infection and Drug Resistance, 2018, Volume 11, 2081-2094.	1.1	11
28	Draft Genome Sequence of a Non-O1/O139 Vibrio cholerae Strain Isolated from a Patient Presenting with Dysuria. Microbiology Resource Announcements, 2018, 7 , .	0.3	3
29	Clinical Features and Laboratory Findings of Travelers Returning to South Australia with Dengue Virus Infection. Tropical Medicine and Infectious Disease, 2018, 3, 6.	0.9	7
30	Dengue Virus Induces Increased Activity of the Complement Alternative Pathway in Infected Cells. Journal of Virology, 2018, 92, .	1.5	28
31	Quantitation of Regulatory Activity for the Complement Alternative Pathway Using an Adaptation of the AP50 in vitro Assay. Bio-protocol, 2018, 8, e3116.	0.2	0
32	<i>FUT2</i> genotype influences lung function, exacerbation frequency and airway microbiota in non-CF bronchiectasis. Thorax, 2017, 72, 304-310.	2.7	35
33	Panblok-H1+advax H1N1/2009pdm vaccine: Insights into rapid development of a delta inulin adjuvanted recombinant pandemic influenza vaccine. Human Vaccines and Immunotherapeutics, 2017, 13, 1261-1271.	1.4	5
34	The Pneumococcal Alpha-Glycerophosphate Oxidase Enhances Nasopharyngeal Colonization through Binding to Host Glycoconjugates. EBioMedicine, 2017, 18, 236-243.	2.7	5
35	Interventions Targeting the Prescribing and Monitoring of Vancomycin for Hospitalized Patients: A Systematic Review Protocol. Infectious Diseases and Therapy, 2017, 6, 557-563.	1.8	6
36	Proteomic analysis of influenza haemagglutinin-specific antibodies following vaccination reveals convergent immunoglobulin variable region signatures. Vaccine, 2017, 35, 5576-5580.	1.7	9

#	Article	IF	Citations
37	A rash diagnosis. Medical Journal of Australia, 2017, 206, 483-484.	0.8	O
38	Junior doctors' preparedness to prescribe, monitor, and treat patients with the antibiotic vancomycin in an Australian teaching hospital. Journal of Educational Evaluation for Health Professions, 2017, 14, 13.	5.9	12
39	Optimizing the detection of methicillin-resistant Staphylococcus aureus with elevated vancomycin minimum inhibitory concentrations within the susceptible range. Infection and Drug Resistance, 2016, 9, 87.	1.1	18
40	Validated Risk Score for Predicting 6â€Month Mortality in Infective Endocarditis. Journal of the American Heart Association, 2016, 5, e003016.	1.6	98
41	Prevalence of macrolide-resistant Mycoplasma pneumoniae in South Australia. Pathology, 2016, 48, 639-642.	0.3	1
42	Human Phase 1 trial of low-dose inactivated seasonal influenza vaccine formulated with Advaxâ,,¢ delta inulin adjuvant. Vaccine, 2016, 34, 3780-3786.	1.7	49
43	Biocompatible anti-microbial coatings for urinary catheters. RSC Advances, 2016, 6, 53303-53309.	1.7	15
44	Frequent isolation of Propionibacterium acnesÂfrom the shoulder dermis despite skinÂpreparation and prophylactic antibiotics. Journal of Shoulder and Elbow Surgery, 2016, 25, 304-310.	1.2	82
45	Effect of sialidase fusion protein (DAS 181) on human metapneumovirus infection of Hep-2 cells. Antiviral Chemistry and Chemotherapy, 2015, 24, 161-165.	0.3	13
46	Pharmacist-led implementation of a vancomycin guideline across medical and surgical units: impact on clinical behavior and therapeutic drug monitoring outcomes. Integrated Pharmacy Research $\&$ Practice, 2015, 4, 145.	0.9	13
47	Use of an Innovative Personality-Mindset Profiling Tool to Guide Culture-Change Strategies among Different Healthcare Worker Groups. PLoS ONE, 2015, 10, e0140509.	1.1	21
48	Interaction between voriconazole and flucloxacillin during treatment of disseminated <i>Scedosporium apiospermum </i> infection. Journal of Antimicrobial Chemotherapy, 2015, 70, 2171-2173.	1.3	13
49	<scp>INITIAT</scp> â€xscp>E. <scp>D</scp> .: <scp>I</scp> mpact of timing of <scp>INITI</scp> ation of <scp>A</scp> ntibiotic <scp>T</scp> herapy on mortality of patients presenting to an Emergency Department with sepsis. EMA - Emergency Medicine Australasia, 2015, 27, 196-201.	0.5	26
50	Impact of Early Valve Surgery on Outcome of Staphylococcus aureus Prosthetic Valve Infective Endocarditis: Analysis in the International Collaboration of Endocarditis–Prospective Cohort Study. Clinical Infectious Diseases, 2015, 60, 741-749.	2.9	84
51	Ocular involvement following <scp>B</scp> acillus <scp>C</scp> almetteâ€ <scp>G</scp> uerin immunotherapy for bladder carcinoma. Clinical and Experimental Ophthalmology, 2014, 42, 494-495.	1.3	7
52	Immunogenicity and safety of Advaxâ,,¢, a novel polysaccharide adjuvant based on delta inulin, when formulated with hepatitis B surface antigen: A randomized controlled Phase 1 study. Vaccine, 2014, 32, 6469-6477.	1.7	81
53	An educational intervention to improve vancomycin prescribing and monitoring. International Journal of Antimicrobial Agents, 2013, 41, 393-394.	1.1	8
54	In-Hospital and 1-Year Mortality in Patients Undergoing Early Surgery for Prosthetic Valve Endocarditis. JAMA Internal Medicine, 2013, 173, 1495.	2.6	215

#	Article	IF	Citations
55	hMPV Lineage Nomenclature and Heparin Binding. Viruses, 2013, 5, 2546-2547.	1.5	1
56	HIV Non-B Subtype Distribution: Emerging Trends and Risk Factors for Imported and Local Infections Newly Diagnosed in South Australia. AIDS Research and Human Retroviruses, 2013, 29, 311-317.	0.5	22
57	Diversity in Glycosaminoglycan Binding Amongst hMPV G Protein Lineages. Viruses, 2012, 4, 3785-3803.	1.5	17
58	Concomitant Septic Arthritis in Crystal Monoarthritis. Journal of Rheumatology, 2012, 39, 157-160.	1.0	32
59	Randomized clinical trial of immunogenicity and safety of a recombinant H1N1/2009 pandemic influenza vaccine containing Advaxâ,,¢ polysaccharide adjuvant. Vaccine, 2012, 30, 5407-5416.	1.7	98
60	Miscellaneous antibacterial drugs. Side Effects of Drugs Annual, 2012, , 399-425.	0.6	1
61	Serological responses following influenza A H1N1 2009 infection in adults. Journal of Infection, 2011, 62, 388-393.	1.7	12
62	Meningitis and Encephalitis., 2010,, 63-66.		0
63	Pneumococcal histidine triad proteins are regulated by the Zn ²⁺ â€dependent repressor AdcR and inhibit complement deposition through the recruitment of complement factor H. FASEB Journal, 2009, 23, 731-738.	0.2	111
64	Multimeric Interactions between Complement Factor H and Its C3d Ligand Provide New Insight on Complement Regulation. Journal of Molecular Biology, 2009, 391, 119-135.	2.0	20
65	The Regulatory SCR-1/5 and Cell Surface-binding SCR-16/20 Fragments of Factor H Reveal Partially Folded-back Solution Structures and Different Self-associative Properties. Journal of Molecular Biology, 2008, 375, 80-101.	2.0	46
66	The role of complement in innate, adaptive and eosinophil-dependent immunity to the nematode Nippostrongylus brasiliensis. Molecular Immunology, 2008, 45, 446-455.	1.0	57
67	Genotypic Diversity of Coagulase-Negative Staphylococci Causing Endocarditis: a Global Perspective. Journal of Clinical Microbiology, 2008, 46, 1780-1784.	1.8	40
68	Functional and Structural Implications of the Complement Factor H Y402H Polymorphism Associated with Age-Related Macular Degeneration., 2008, 49, 1763.		85
69	Phylogenetic Analysis of Viridans Group Streptococci Causing Endocarditis. Journal of Clinical Microbiology, 2008, 46, 3087-3090.	1.8	28
70	Emergence of Coagulase-Negative Staphylococci as a Cause of Native Valve Endocarditis. Clinical Infectious Diseases, 2008, 46, 232-242.	2.9	160
71	Cat Got Your Tongue?. Clinical Infectious Diseases, 2008, 46, 146-146.	2.9	30
72	Role of Cellular Glycosaminoglycans and Charged Regions of Viral G Protein in Human Metapneumovirus Infection. Journal of Virology, 2008, 82, 11767-11774.	1.5	59

#	Article	IF	Citations
73	Analysis of the First Australian Strains of Bartonella quintana Reveals Unique Genotypes. Journal of Clinical Microbiology, 2007, 45, 2040-2043.	1.8	9
74	Mannose-binding lectin deficiency does not increase the prevalence of Helicobacter pylori seropositivity. European Journal of Gastroenterology and Hepatology, 2007, 19, 147-152.	0.8	8
75	Mannose-binding lectin and gastric cancer. International Journal of Cancer, 2007, 120, 2751-2752.	2.3	0
76	Localization of the third heparin-binding site in the human complement regulator factor H1. Molecular Immunology, 2006, 43, 1624-1632.	1.0	62
77	Surgical antisepsis and the risk of operating theatre fires. ANZ Journal of Surgery, 2006, 76, 422-423.	0.3	5
78	Molecular Analyses of the Interaction of Borrelia hermsii FhbA with the Complement Regulatory Proteins Factor H and Factor H-Like Protein 1. Infection and Immunity, 2006, 74, 2007-2014.	1.0	63
79	Demonstration of Factor H-Like Protein 1 Binding to Treponema denticola, a Pathogen Associated with Periodontal Disease in Humans. Infection and Immunity, 2005, 73, 7126-7132.	1.0	42
80	Loss of Complement Activation and Leukocyte Adherence as Nippostrongylus brasiliensis Develops within the Murine Host. Infection and Immunity, 2005, 73, 7442-7449.	1.0	25
81	Binding of Complement Factor H to Endothelial Cells Is Mediated by the Carboxy-Terminal Glycosaminoglycan Binding Site. American Journal of Pathology, 2005, 167, 1173-1181.	1.9	108
82	Paradoxical Inflammatory Reaction during Treatment of Cryptococcus neoformans var. gattii Meningitis in an HIV-Seronegative Woman. Clinical Infectious Diseases, 2004, 39, e78-e82.	2.9	61
83	Quantitation of complement and leukocyte binding to a parasitic helminth species. Journal of Immunological Methods, 2004, 289, 201-210.	0.6	9
84	A common site within factor H SCR 7 responsible for binding heparin, C-reactive protein and streptococcal M protein. European Journal of Immunology, 2003, 33, 962-969.	1.6	151
85	Identification of the Streptococcal M Protein Binding Site on Membrane Cofactor Protein (CD46). Journal of Immunology, 2002, 168, 4585-4592.	0.4	60
86	The Human Complement Regulator Factor H Binds Pneumococcal Surface Protein PspC via Short Consensus Repeats 13 to 15. Infection and Immunity, 2002, 70, 5604-5611.	1.0	76
87	Multiple ligand binding sites on domain seven of human complement factor H. International Immunopharmacology, 2001, 1, 433-443.	1.7	50
88	Complement C3b interactions studied with surface plasmon resonance technique. International Immunopharmacology, 2001, 1, 495-506.	1.7	49
89	Amoebic liver abscess in pregnancy. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2001, 41, 236-237.	0.4	6
90	Complement factor H: sequence analysis of 221 kb of human genomic DNA containing the entire fH, fHR-1 and fHR-3 genes. Molecular Immunology, 2000, 37, 41-52.	1.0	56

#	Article	lF	Citations
91	Epoxy resin allergy from microscopy immersion oil. Australasian Journal of Dermatology, 1999, 40, 228-229.	0.4	25
92	Concurrent infection due to Shewanella putrefaciens and Mycobacterium marinum acquired at the beach. Australasian Journal of Dermatology, 1998, 39, 92-95.	0.4	28
93	M Protein of the Group A Streptococcus Binds to the Seventh Short Consensus Repeat of Human Complement Factor H. Infection and Immunity, 1998, 66, 1427-1431.	1.0	99
94	Cloning and analysis of the human complement factor H gene promoter. Immunology and Cell Biology, 1997, 75, 508-510.	1.0	11
95	The Delta trial. Lancet, The, 1996, 348, 1238-1239.	6.3	1
96	Emerging resistance in <i>Enterococcus</i> spp Medical Journal of Australia, 1996, 164, 116-120.	0.8	41
97	CHEST WALL ACTINOMYCOSIS IN ASSOCIATION WITH THE USE OF AN INTRA-UTERINE DEVICE. ANZ Journal of Surgery, 1995, 65, 141-143.	0.3	8
98	Effect of needle changing and intravenous cannula collection on blood culture contamination rates. Annals of Emergency Medicine, 1993, 22, 1164-1168.	0.3	19
99	CUTANEOUS CRYPTOCOCCOSIS: RECURRENCE FOLLOWING ORAL FLUCONAZOLE TREATMENT. Australasian Journal of Dermatology, 1992, 33, 93-96.	0.4	4
100	Detection of complement protein mRNA in human astrocytes by the polymerase chain reaction. Journal of Neuroscience Methods, 1992, 45, 191-197.	1.3	31
101	Is primary sensitivity testing on urine samples valid?. Pathology, 1991, 23, 149-152.	0.3	7
102	Surface phagocytosis of Staphylococcus epidermidis and Escherichia coli by human neutrophils: serum requirements for opsonization and chemiluminescence. FEMS Microbiology Letters, 1989, 47, 417-424.	0.7	9
103	Analysis of C3 Deposition and Degradation on Bacterial Surfaces After Opsonization. Journal of Infectious Diseases, 1988, 157, 697-704.	1.9	93
104	Serum bactericidal activity against Haemophilus influenzae. Pathology, 1988, 20, 124-129.	0.3	2
105	Capnocytophaga species: A cause of amniotic fluid infection and preterm labour. Pathology, 1988, 20, 74-76.	0.3	20
106	CRYPTOCOCCAL INFECTION SIMULATING VARICELLA. Australasian Journal of Dermatology, 1987, 28, 24-26.	0.4	4
107	Complement and host defence against microorganisms. Pathology, 1986, 18, 365-375.	0.3	19